Home Corporate Overview Human Medicine Veterinary Medicine Publications News Investor Relations Careers Contact Relations Investisseurs Accueil PHARMACEUTICAL COMPANY Our vision is to continuously deliver innovative therapeutic drugs that will significantly improve the health of patients. LATEST NEWS First half of 2017 results 31/08/2017 - AB Science reports its revenues for the first half of 2017 and provides an update on its activites AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients with pain until 2033 12/07/2017 - Recruitment target before possible resampling of masitinib confirmatory study in pancreatic cancer has been reached AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association (EHA) 22/06/2017 - Abstract selected for presentation by the EHA Scientific Program Committee AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meeting 18/05/2017 - Study was a success showing masitinib to be safe and effective treatment in ALS AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings 17/05/2017 - AB Science will ask for a re-examination with the opinion of Scientific Advisory Group (SAG) to evaluate the benefit-risk balance PRODUCT INQUIRIES © COPYRIGHT AB SCIENCES. ALL RIGHTS RESERVED. I MASIVET® I KINAVET® I LEGAL NOTICE I DESIGN : AGENCE K2

Home Corporate Overview Human Medicine Veterinary Medicine Publications News Investor Relations Careers Contact Relations Investisseurs Accueil Overview Masitinib in oncology Masitinib in inflammatory diseases Masitinib in neurodegenerative disease Other compounds Masitinib is developed in several human indications, in oncology, inflammatory diseases, and central nervous system diseases. Masitinib has been evaluated in around 4000 human patients to date. Masitinib also generated positive phase 2 results in oncology, inflammatory diseases, as well as CNS diseases. Several phases 3 are on-going in those indications. AREA INDICATION STUDY STATUS Oncology / Hematology GIST in first-line treatment Phase 3 On-going GIST in second-line treatment Phase 3 On-going Metastatic melanoma with JM mutation of c-KIT Phase 3 On-going Pancreatic cancer Phase 3 On-going Relapsed metastatic colorectal cancer Phase 3 On-going Castrate Resistant Prostate Cancer in first line Phase 3 On-going Relapsed metastatic ovarian cancer Phase 3 On-going Relapsed peripheral T-cell lymphoma Phase 3 On-going Inflammatory and neuro-degenerative diseases Severe asthma uncontrolled by oral corticosteroids Phase 3 Recruitment completed Severe asthma uncontrolled by oral corticosteroids and with elevated eosinophil level Phase 3 On-going Alzheimer disease Phase 3 On-going Progressive forms of multiple sclerosis Phase 3 On-going Amyotrophic lateral sclerosis Phase 3 Study completed © COPYRIGHT AB SCIENCES. ALL RIGHTS RESERVED. I MASIVET® I KINAVET® I LEGAL NOTICE I DESIGN : AGENCE K2